Field report SE-14 / L8 · sheet /expansion
Expansion & MarketsFiled from the territory
Theramex in FDA talks as U.S. estradiol prescriptions hit 4 million
Theramex scaled manufacturing and is discussing a special FDA import, with U.S. estradiol prescriptions doubling in two years to 4 million a month.
- Grid
- SE-14 / L8
- Surveyed
- November 20, 2026
- Reading
- 3 min read
- Correspondent
- Amara Osei

Field notes
- U.S. prescriptions containing estradiol doubled in two years to 4 million a month, per Symphony Health data
- Theramex expanded manufacturing; CEO Robert Stewart says monthly U.S. patch shipments would be "substantial"
- The American Society of Health-System Pharmacists has listed estrogen patches as in shortage since January
- FDA began softening its warnings on heart, breast cancer and dementia risks a year ago, and prescription growth accelerated after
- Theramex plans to seek full FDA approval for its patches in the first six months of 2027
U.S. prescriptions containing estradiol, a form of estrogen, have doubled in two years to 4 million a month, and London-based Theramex is now in discussions with the Food and Drug Administration about supplying the American market.
Theramex has already expanded manufacturing capacity in anticipation that the agency might authorize sales, chief executive Robert Stewart told Bloomberg. U.S. women have struggled to obtain estrogen patches as demand climbed, and the shortfall has pushed the company into a regulatory channel normally reserved for exceptional cases.
"We've been in dialogue with the FDA," Stewart said, according to Bloomberg. "They have the information that they would need to be able to issue a special import, and if they do, we'd be able to immediately respond."
What does the FDA need to authorize?
The FDA (the agency that approves and regulates medicines in the United States) retains discretion in exceptional cases to allow drugmakers to market products it has not approved, for a limited period. Theramex holds no approved products in the U.S.
Unless a shortage has been declared, that route remains uncommon. The American Society of Health-System Pharmacists has listed estrogen patches as being in shortage since January, though the FDA does not classify them as in short supply nationwide, citing company data on supply, demand and expected future demand.
An FDA spokesperson declined to discuss the details or timing of any step the agency might take regarding Theramex. The spokesperson said that when patients struggle to obtain their medications, the agency can draw on a number of options, temporary importation among them.
Why are prescriptions doubling?
The increase gathered pace once the FDA, a year ago, began softening its warnings on the risks of heart problems, breast cancer and dementia linked to the drugs.
"We know for some patients these past few months have been frustrating," Sarah Ibrahim, deputy director for regulatory programs at the FDA's drug center, said on an Oct. 30 call with reporters. She said the agency is working to address the problem.
What has Theramex done to prepare?
Stewart said Theramex contacted the FDA since the summer. Conversations have become more specific and higher level over the past month, he said, as it became clearer that demand would outstrip manufacturers' capacity.
If Washington clears the sale, the number of patches sent each month would be "substantial," Stewart said. He said customers in other markets would not be affected by the move.
Theramex markets Evorel, an estrogen patch sold in the U.K. for relief of menopause and perimenopause complaints such as night sweats and hot flashes. The company intends to seek full FDA approval for its patches during the first six months of 2027.
The company also holds early discussions with an unnamed business partner about U.S. distribution, in case the product clears sooner. Stewart declined to name the partner.
Stewart was previously chief executive of Amneal Pharmaceuticals, which ranks among the top U.S. sellers of estrogen patches alongside Viatris and Sandoz Group.
The timeline in brief
- Estradiol prescriptions in the U.S.: 4 million a month, doubled over two years, according to Symphony Health data cited by Bloomberg.
- American Society of Health-System Pharmacists shortage listing for estrogen patches: since January.
- FDA softening of warnings on heart, breast cancer and dementia risks: one year ago, after which prescription growth accelerated.
- Theramex's contact with the FDA: since the summer, with more specific discussions over the past month.
- Intended FDA approval filing for Theramex patches: first six months of 2027.
- Monthly U.S. patch shipments under a special import: "substantial," according to Stewart.
via qz.com (Source)
More from Amara Osei
Show full bio
Market editor covering people, launches and day-to-day practice in corporate strategy and chief-executive leadership at CEO Frontier.
479 articles
Adjacent sheets
- HHS Opens Pharmacy Channel for Six Unapproved Peptides
- Roche Lines Up Wilserdly Brand for Breast Cancer Pill Giredestrant
- Novo Nordisk's Wegovy Pill Beats Expectations, but Injections Slide
- Ultragenyx Cuts 10% of Workforce as FDA Stalls Gene Therapy Plans
- Aspen cleared to sell generic Ozempic and Wegovy in three markets